HomeGGL aims to be a global integrated Generic and API leader. The Company currently markets finished dose formulations in USA, Europe, and Argentina and has Active Pharmaceutical Ingredients (APIs) presence in over 80 countries through an established group of subsidiaries, marketing front-ends and offices in India and select overseas locations.
GGL has a strong base in Formulations development with teams operating out of laboratories in India and Latin America. The Company posted a growth of 25 % on business with revenues of USD 212.12 Mn.The Company has a state-of-the-art manufacturing plant at Goa, India that is approved by US FDA, TPD (Canada), MHRA, UK and many other overseas regulatory authorities. GGL also markets over 45 APIs to more than 80 countries across the world and had over 35 USDMFs filed and/or approved along with several DMFs in Canada.
Glenmark’s API division possesses strong, dedicated process research capabilities and a dedicated team of scientists equipped with the best analytical tools and a sophisticated information centre. Currently, GGL has three API manufacturing plants in India of which its plant at Ankhleshwar is approved by USFDA and several other overseas regulatory bodies.
Snapshot
- The Generics business has been built over the last 4-5 years
- Comprising of US & EU generics, API and Argentina Oncology SBUs
- GGL focuses on developing, manufacturing, selling, and the distribution of generics through wholesalers, retailers and pharmacy chains etc
- End to End vertically integrated into the generic market (From API to front end marketing capabilities)
- Focused on certain key niche market segments including; Dermatology, Hormones, Controlled Substances, Oncology, and Modified Release
- Currently wholly owned by GPL
Corporate Office:
Glenmark Generics Limited
Glenmark House, HDO - Corporate Bldg, Wing A
B D S Marg, Chakala, Off Western Express Highway
Andheri (E), Mumbai - 99, India
Contact:
Tel: +91 22 4018 9999
Fax: +91 22 4018 9999
